The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1-3), estrogen-receptor-positive (ER+), postmenopausal early breast cancer (EBC) patients.
involving node-positive postmenopausal breast cancer patients, to investigate the impact of tamoxifen, an epirubicin-containing chemotherapy regimen, and a combination of these two treatments on disease-free (DFS) and overall survival (OS), in comparison with a control group not receiving adjuvant therapy [20] . In 1991, we initiated a second trial, FASG 07, in postmenopausal women to compare tamoxifen with chemoendocrine therapy in patients with one to three positive nodes (N1-3) and HR+ tumor [21] . We present here individual data of each trial and pooled data of both studies in N1-3, estrogen-receptor-positive (ER+) patients comparing tamoxifen with chemoendocrine therapy.
patients and methods study population
Between 1986 and 1990, 776 node-positive women with operable breast cancer were randomized in the FASG 02 trial, irrespective of hormone receptors status. The FASG 07 was initiated in 1991 and ended in 1998, enrolling 335 one to three node-positive (N1-3), hormone-receptor-positive (HR+) patients. The distribution of patients is described in Table 1 . Both studies recruited postmenopausal women aged from 50 to 65 years, with last menses occurring more than 1 year previously. Estrogen and/or progesterone receptors positivity was defined as an upper value of 10 fmol/mg proteins. The women had all undergone modified radical mastectomy or lumpectomy plus axillary dissection (at least five axillary lymph nodes resected). The main eligibility criteria were World Health Organization (WHO) performance status £2, normal hematologic (granulocyte count ‡2000/mm 3 , platelet count ‡100 000/mm 3 ), hepatic (bilirubin £35 lmol/l) and renal (serum creatinine level £130 lmol/l) functions, and no cardiac dysfunction (left ventricular ejection fraction, LVEF ‡50%). LVEF was measured at rest by radioisotopic or ultrasonographic methods. Patients were excluded from the study if they had evidence of metastases, a documented history of cardiac disease or previous cancer (except treated basal cell and squamous cell carcinoma of the skin or cancer of the uterine cervix), a serious underlying medical illness or psychiatric disorder, inflammatory or locally advanced breast cancer before surgery, previous radiation therapy, or hormonotherapy or chemotherapy for breast cancer, or if treatment start exceeded 42 days from initial surgery for breast cancer. Potentially eligible patients also underwent bone scan, chest radiograph, abdominal ultrasound or computed tomographic scan, and contralateral mammography. Written informed consent was obtained from each patient in a standard procedure at each participating institution. (Table 1) .
Locoregional radiotherapy was delivered within 6 weeks after initial surgery in Tam or control groups. In the FASG 02 trial, it was delivered within 15 days after the third chemotherapy cycle, and then patients received the fourth chemotherapy cycle within 15 days after completing radiotherapy. Radiotherapy was delivered within 30 days after the last chemotherapy cycle in the FASG 07 trial. After mastectomy, radiation to the chest wall, supraclavicular area, internal mammary chain and, in the case of pN1 tumor, to the axillary area, was delivered and consisted of 50 Gy in 25 fractions for each target. Patients who underwent lumpectomy received local radiation to the breast, which consisted of 55 Gy in 27 fractions plus a complementary breast irradiation of 10-15 Gy and local radiation to the supraclavicular area, internal mammary chain and axillary area (in the case of pN1 tumor) consisting of 50 Gy in 25 fractions for each target.
For chemotherapy, preventive use of granulocyte-colony stimulating factor (G-CSF) and antibiotics were prohibited. An absolute granulocyte count of less than 2000/mm 3 or a platelet count of less than 100 000/mm 3 on day 21 led to a treatment interruption of at least 1 week. Treatment was stopped if hematologic recovery took more than 3 weeks. The epirubicin dose was reduced by 50% if serum bilirubin levels were 35-50 lmol/l and treatment was stopped if bilirubin levels exceeded 50 lmol/l. The tolerability of chemotherapy was evaluated before each cycle: an ECG and a complete blood count were performed on day 21, and nonhematologic toxicity was evaluated during the period between each cycle, according to WHO criteria. Subjects underwent clinical and biochemical assessments every 6 months during the 5-year follow-up period and yearly thereafter. A radiological assessment was performed every year during the 5-year follow-up period and every 2 years thereafter.
statistical analysis
Individual data of each trial were analyzed separately. All assessable patients were entered onto an intention-to-treat analysis using SPSS software (SPSS Inc., Chicago, IL). The FASG 02 trial was designed as a 2 · 2 factorial plan in order to compare hormonotherapy and chemotherapy. compare baseline categorical variables and the incidence of adverse events in both groups [22] . Continuous variables were compared using analysis of variance [23] . DFS and local-DFS were defined as the time from random allocation until first relapse (local, regional and distant) or first ipsilateral relapse, respectively. A contralateral breast cancer was considered a new primary malignancy. Overall survival (OS) was defined as the time from random assignment until death, whether or not it was related to breast cancer. DFS, local-DFS and OS rates were computed according to the Kaplan-Meier method, and survival curves were compared with the logrank test or log-rank test stratified on the study for the pooled analysis [24, 25] . The Cox regression analysis was stratified on the study and adjusted for adjuvant treatment, age, surgical procedure, Scarff-Bloom and Richardson (SBR) grade, pathologic tumor size (pT) and progesterone receptors (PR) [26] . Statistical analysis has been performed in a doubleblind fashion both by Pfizer, France and by an independent biostatistician. results
patient and treatment characteristics
In each study, baseline characteristics were well balanced among treatment arms. When clinical and pathologic characteristics were compared between both studies, they were significantly different for all variables (Table 2) . Noteworthy, in the FASG 07 trial, it was mandatory to have estrogen and/or progesterone positive receptors. In this study, 99% of the patients were ERpositive and one patient had unknown PgR. In the FASG 02 trial, as hormone receptor status was not a screening criteria, more than 20% of the patients had no assessment of HR and the Table 2 . Clinical and pathologic characteristics in FASG 02 and FASG 07 trials, and per treatment arm in N1-3, ER+ patients of pooled analysis.
Pooled analysis 
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same rate had ER-negative tumor. In N1-3, ER+ patients assessable for pooled efficacy analysis, these characteristics were comparable among Tam and FEC50-Tam arms (Table 2 ). This allowed comparison of treatment arms in this population. Treatment characteristics and compliance to adjuvant therapy are described in Table 3 . Patients received locoregional radiotherapy in 94% of the cases. Radiotherapy modalities were similar in both studies regarding sites irradiated and doses delivered. In 517 patients receiving chemotherapy, 361 (70%) received radiotherapy between the third and the fourth cycle.
survival analysis FASG 02. The median follow-up was 134 months (range 4-202). The incidence of relapse, local relapse and death, as well as 11-year DFS, local-DFS and OS rates are shown in Table 4 ( Figures 1A, 2A) . Per study design, the 2 · 2 factorial plan showed a significant benefit of hormonotherapy compared with the absence of hormonotherapy for both 11-year DFS and OS (62% versus 46%, P < 0.0001; 65% versus 54%, P = 0.002, respectively). There was no advantage of chemotherapy (54% versus 52%, P = 0.35; 61% versus 59%, P = 0.14, respectively). CI 1.85-2.65, P = 0.0001), as the absence of chemotherapy did not modify disease outcome (HR = 1.39, 95% CI 0.97-1.81, P = 0.12). There was no interaction between hormonotherapy and chemotherapy (P = 0.76), and hence the model can be considered additive. FASG 07. The median follow-up was 89 months (range 28-140). The incidence of relapse, local relapse and death, as well as 8-year DFS, local-DFS and OS rates, are shown in Table 4 ( Figures 1B, 2B) . In terms of relapse, the advantage of chemoendocrine therapy over hormonotherapy remained significant in the multivariate model (HR = 0.44, 95% CI 0.00-0.99, P = 0.004) and pT was the only independent prognostic factor (HR = 0.30, 95% CI 0.00-0.88, P = 0.0001).
Pooled analysis. The median follow-up was 113 months (range 4-202). The incidence of relapse, local relapse and death, as well as 9-year DFS, local-DFS and OS rates, are shown in Table 4 ( Figures 1C, 2C) . In terms of relapse, the advantage of chemoendocrine therapy over hormonotherapy remained significant in the multivariate analysis (P = 0.0008) and pT was the only independent prognostic factors (P = 0.002) ( Table 5) . As regards death, no prognostic factor was statistically significant. There was a trend for improvement in survival in favor of chemoendocrine therapy (P = 0.07).
acute toxicity
Chemotherapy acute toxicity was evaluated according to WHO criteria and was typical of those observed with six cycles of FEC 50 [19, 27] . This toxicity was not different between both trials and was similar in patients who received no concurrent Tam. Hormonotherapy was stopped prematurely in 119 (17%) patients. The main reasons for Tam interruption were: relapse (n = 91), toxicity (n = 14), gynecologic disturbances (n = 5), endometrial carcinoma (n = 1), patient's refusal (n = 2), protocol violation (n = 1), second malignancy (n = 5), Guillain-Barre syndrome (n = 1) and death (n = 5: suicide, cirrhosis, traffic accident, and unknown reasons in 2). Fifty-nine (11%) patients did not receive the complete schedule of chemotherapy for the following reasons: patient's refusal (n = 17), digestive toxicity (n = 7), hematologic toxicity (n = 5), cardiac toxicity (n = 6), infection (n = 3), radiotherapy injury (n = 3), venous injury (n = 3), late discovery of initial metastatic breast cancer (n = 4), relapse (n = 2), protocol violation (n = 2), lost to follow-up (n = 3) and unknown reason (n = 4). As regards hematologic toxicity, grade 3-4 neutropenia occurred in 13% of the patients without preventive use of G-CSF; three cases (0.6%) of grade 3 infection were reported; no case of grade 3-4 anemia occurred and grade 1-2 anemia was observed in 19%; a thrombocytopenia was observed in 1% of patients. The other severe side-effects observed were: grade 3-4 nausea-vomiting in 24% of patients without anti 5-HT3 prophylaxis, five cases (1%) of grade 3 stomatitis, and grade 3 alopecia in 23%. No toxic death was registered. Four patients presented with a left ventricular dysfunction: LVEF was <50% in two (no baseline value available in both cases), a reduction in LVEF of 18% in one, and worsening of a pre-existing left ventricular hypertrophia in one. In 11 patients, conduction or rhythm disturbances were diagnosed. None of these 15 patients presented with subsequent cardiac clinical symptoms.
delayed cardiac events
Cardiac events occurring during the follow-up period are described in Table 6 . Overall, a severe cardiac event was reported in six patients who did not receive adjuvant chemotherapy (1.1%), and in six patients who received epirubicin-based adjuvant chemotherapy (1.1%).
In patients who were free of anthracycline either in the adjuvant setting or in the metastatic setting, two CHF occurred of whom one patient died as a result of the CHF, one patient developed a left ventricular hypertrophia, one had a transient decrease in LVEF and one had a myocardial infarct. One patient who received Tam in the adjuvant setting, then 400 mg/m 2 of epirubicin for her metastatic disease had a non-complicated LVEF decrease.
In patients who received FEC50 or FEC50-Tam, one died of CHF (0.2%), one died of myocardial infarct (previous myocardial infarct before randomization), one died of a cardiogenic shock related to an anemia after receiving mitoxantrone-based first-line chemotherapy, and three had non-complicated decrease in LVEF.
second malignancies
Overall, 38 patients (3.5%) developed a contralateral breast cancer: 28 cases (3.7%) in the FASG 02 trial and 10 cases (3.1%) in the FASG 07 trial. The median onset was 60 months (range 4-149 months). There was no difference between studies and treatment groups for incidence and onset period.
Second malignancies occurred in 58 patients (5.4%): seven in the control arm (3.8%), 16 in Tam arms (4.5%), 10 in the FEC50 arm (5.4%) and 25 in FEC50-Tam arms (7.2%). Fifteen 2 ). This case was probably related to mitoxantrone (18 months after initiation of mitoxantrone). The remaining 41 cases were: lymphoma (1), myeloma (1), ovarian carcinoma (7), cervical neoplasia (4), digestive tract carcinoma (15) , lung carcinoma (1), head and neck carcinoma (1), thyroid carcinoma (3), kidney carcinoma (2), basocellular carcinoma (5) and sarcoma (1).
discussion
The FASG 02 trial was not designed to compare tamoxifen and chemoendocrine therapy directly but to evaluate the respective contribution of hormonotherapy and chemotherapy in node-positive postmenopausal patients. If the role of tamoxifen was clear, we failed to demonstrate the contribution of chemotherapy. The results of chemotherapy were probably decreased by the arm containing only chemotherapy without tamoxifen, which was clearly a wrong approach in this subset of patients. The FEC50-Tam arm was superior for DFS, local-DFS and OS. As no interaction was found between hormonotherapy and chemotherapy, the model can be considered additive. The FASG 07 trial compared tamoxifen and chemoendocrine therapy directly and we showed a significant advantage of FEC50-Tam over Tam in terms of DFS in a favorable subset of node-positive, postmenopausal women. As regards OS, the low number of events did not demonstrate a difference between treatment arms. The pooled analysis of both trials reinforced and confirmed the results obtained in the FASG 07 trial. This analysis allowed us to demonstrate an improvement in local-DFS and a trend in a better OS with chemoendocrine therapy in spite of a relatively modest number of deaths. However, our results have the limitation of a retrospective and pooled analysis. Patient population of the two studies is not similar: in the FASG 02 trial, patients were treated irrespective of hormone receptor status (42% of ER negative/unknown) and 38% of them presented with nodes involvement superior than three nodes.
The contribution of chemotherapy in postmenopausal women remains controversial. In 1995, the Oxford meta-analysis concluded that, in patients older than 50 years and ER+, the reduction in risks of relapse and death was superior with tamoxifen than with chemotherapy [28] . However, benefits obtained with both treatments could be considered additive. Recently, the International Breast Cancer Study Group (IBCSG) trial compared tamoxifen alone with tamoxifen combined with three cycles of CMF in 608 node-positive, postmenopausal women [29] . The 5-year DFS was significantly better with chemoendocrine therapy (P = 0.03), whereas no difference was observed in terms of OS. In the Oxford meta-analysis, anthracycline-based chemotherapy showed a significant improvement in DFS and OS over CMF, irrespective of age, ER and nodal status [28] . The Southwest Oncology Group (SWOG) compared CAF regimen plus tamoxifen (concurrent or sequential) to tamoxifen alone. Chemotherapy added a significant 10-year DFS and OS benefit to tamoxifen in postmenopausal, node-positive, HR+ patients [30] . Using epirubicin single-agent combined with tamoxifen, two studies demonstrated the advantage of the association in postmenopausal, node-positive patients after 5-6 years of follow-up [31, 32] . Among these patients, 27% and 100% of patients were older than 65 years, respectively. The contribution of chemotherapy in node-positive, postmenopausal patients has recently been presented with taxanes. Surprisingly, the addition of three cycles of docetaxel after three cycles of FEC 100 significantly improved 5-year DFS compared with six cycles of FEC 100, whereas no advantage was found in premenopausal women [33] . Overall, our study confirmed the advantage of an anthracycline-based chemotherapy combined with tamoxifen in HR+, postmenopausal patients. We found that this benefit 
